Although IDH mutation status in newly diagnosed and recurrent gliomas can be reliably assessed using multi‐parametric MRI, the greater spatial and temporal variability of EGFR amplification complicates its imaging‐based characterization. This evidence concerns the gene IDH1 and glioma.